ULTOMIRIS® (ravulizumab-cwvz) injection for intravenous use 300 mg/30 mL vial
Menu

Important information regarding COVID-19 and access to your medicine

We understand that you may be concerned about how the evolving COVID-19 situation could impact access to your medicine.

Alexion’s goal is to always manage a robust supply chain that delivers medicines that are secure, sterile, and meet our rigorous quality standards. In addition, due to the seriousness of the diseases we treat, we strive to maintain sufficient inventory levels to ensure their supply to the patients who rely on them. We have taken proactive measures to mitigate the risk of potential interruptions in supply, and we are continuing to actively monitor this dynamic and rapidly evolving situation worldwide.

In the current COVID-19 pandemic, the American Society of Hematology (ASH) – the world’s largest professional society of hematologists – recommends that patients with PNH who require ULTOMIRIS should stay on it because of the risk of serious and irreversible blood clots. ASH also recommends ULTOMIRIS as the preferred treatment option due to the fact that 8-week dosing minimizes visits to a physician’s office or infusion center. Talk to your doctor to learn more about what’s right for you [https://www.hematology.org/covid-19/covid-19-and-aplastic-anemia].

Alexion will continue to support community activities during this time. While externally organized events are being cancelled or postponed, we will continue to work with [patient advocacy organizations, congress organizers, etc.] to review requests and support programs when possible.

Alexion is hosting virtual education events about disease and treatment. Contact OneSource for more information at 1.888.765.4747.

Moving forward,

  • Continue to follow your physician’s advice about your specific medical situation
  • Follow directions provided by your local government

For more information on the evolving COVID-19 pandemic, please monitor public health authority websites, such as www.cdc.gov or www.who.int.

  1. Data on file. Alexion Pharmaceuticals, Inc.; 2019.
  2. SOLIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; June 2019.
  3. ULTOMIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; October 2019.
  4. Sheridan 2018/p13/para3/line8-10
  5. Levy, AR, et al. 2019
  6. Olie KH et al. Am J Kidney Dis. 2005;45(1):e12–e15
  7. Berner R et al. Pediatric Nephrology.2002;17(3):190–192.
  8. Brodsky RA et al. Haematologica. E-pub ahead of print, Jan 16, 2020.
  9. Ueda T et al. Journal of Nippon Medical School. 2013;80(2):155–159, Brodsky 2020/p12/para1/lines2-3
  10. EU Society of Bone Marrow and Transplant Patients, http://www.pnhleeds.co.uk/coronavirus/
  11. http://www.atypicalhus.co.uk/

Now FDA approved 100 mg/mL formulation: get the details

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

Show more Show less
Show less

ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

  • ULTOMIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
  1. You must receive meningococcal vaccines at least 2 weeks before your first dose of ULTOMIRIS if you are not vaccinated.
  2. If your doctor decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible.
  3. If you have not been vaccinated and ULTOMIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
  4. If you had a meningococcal vaccine in the past, you might need additional vaccination. Your doctor will decide if you need additional vaccination.
  5. Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms and eyes sensitive to light.

Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your doctor must: enroll in the ULTOMIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a Patient Safety Card about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with a meningococcal vaccine, and if needed, get revaccinated with the meningococcal vaccine. Ask your doctor if you are not sure if you need to be revaccinated.

ULTOMIRIS may also increase the risk of other types of serious infections. Make sure your child receives vaccinations against Streptococcus pneumoniae and Haemophilis influenzae type b (Hib) if treated with ULTOMIRIS. Call your doctor right away if you have any new signs or symptoms of infection.

Who should not receive ULTOMIRIS?

Do not receive ULTOMIRIS if you have a meningococcal infection or have not been vaccinated against meningococcal infection unless your doctor decides that urgent treatment with ULTOMIRIS is needed.

Before you receive ULTOMIRIS, tell your doctor about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your doctor about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

If you have PNH and you stop receiving ULTOMIRIS, your doctor will need to monitor you closely for at least 16 weeks after you stop ULTOMIRIS. Stopping ULTOMIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in your red blood cell count, tiredness, blood in your urine, stomach-area (abdomen) pain, shortness of breath, blood clots, trouble swallowing, and erectile dysfunction (ED) in males.

What are the possible side effects of ULTOMIRIS?

ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, pain with the infusion, feeling faint or discomfort in your arms or legs. Tell your doctor or nurse right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people treated for PNH are upper respiratory infection and headache.

Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your doctor or pharmacist. Call your doctor right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

What is ULTOMIRIS?

ULTOMIRIS is a prescription medicine used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). It is not known if ULTOMIRIS is safe and effective in children with PNH.

Please see the accompanying full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.